Intelligence Β· INN directory
Pharmaceutical Drugs
Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.
Quick answer
NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse AβZ for competitive intelligence and medical affairs reference.
Recently updated
FDA-approved
-
venlafaxine besylate
VENLAFAXINE BESYLATE
-
vepdegestrant
VEPPANU
-
veratrum viride root
VERTAVIS
-
vericiguat
VERQUVO Bayer Australia Ltd
C01 -
verteporfin
VISUDYNE
S01LA01 -
vibegron
OBGEMSA
G04BD15 -
vidarabine
VIRA-A
-
viltolarsen
VILTEPSO
-
vimseltinib
ROMVIMZA
L01EX -
vinblastine sulfate
VINBLASTINE SULFATE
-
viomycin sulfate
VIOCIN SULFATE
-
vismodegib
ERIVEDGE Hoffmann-La Roche
L01XX43 -
vitamin a
VITAMIN A
-
vorapaxar sulfate
ZONTIVITY
-
vorasidenib
VORANIGO
L01XM04 -
vorinostat
ZOLINZA Merck KGaA, Darmstadt, Germany
-
vortioxetine
BRINTELLIX
N06AX26 -
voxelotor
OXBRYTA
B06AX03 -
warfarin potassium
ATHROMBIN-K
-
xenon xe-127
XENON XE 127
-
xenon xe-129 hyperpolarized
XENOVIEW
-
xylose
XYLOSE
-
zafirlukast
ZAFIRLUKAST
-
zalcitabine
HIVID
Frequently asked questions
What is the NovaPharmaNews drugs directory?
It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.
Where does drug approval data come from?
Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.
How do I find a drug by brand name?
Use the search box on this page β it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.